Expanded Access to Telisotuzumab Vedotin

Sponsor
AbbVie
Study ID
NCT04830202
Status
Temporarily Not Available

Conditions

  • Non-Small Cell Lung Cancer (NSCLC)

Eligibility Criteria

Sex
All
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to Telisotuzumab vedotin prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

Key Dates

Status verified
May 2026

Related Studies